Long-term Outcome of TNF Alpha Therapy in IBD

NCT04575701 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 538

Last updated 2021-02-25

No results posted yet for this study

Summary

The aim of this retrospective study is to assess the outcome of patients with inflammatory bowel disease (IBD) under TNF-alpha antibody therapy over a period of 20 years

Conditions

Interventions

OTHER

TNF Alpha therapy

Retrospective analysis of outcome of first TNF Alpha therapy

Sponsors & Collaborators

  • Medical University of Graz

    lead OTHER

Principal Investigators

  • Wolfgang Petritsch, Prof · Meduni Graz

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-01
Primary Completion
2020-06-01
Completion
2020-07-01

Countries

  • Austria

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04575701 on ClinicalTrials.gov